DexTech Medical's application for myeloma study approved

The application for a phase1 study regarding OsteoDex's effect on patients with multiple myeloma that was submitted to the Medical Products Agency on 2022-06-23 has been approved and granted permission 2022-08-10. The study will include 20 patients and be conducted at 5 hospital centers in Sweden and Norway. The start of the study is expected to be Q3-2022 - Q1-2023 and is expected to be completed Q3-2024.

For more information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-post: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 10 August 2022.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the result shows high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate after completing the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.